
WFH publishes new AAV gene therapy guidelines
The World Federation of Hemophilia (WFH) has published a new evidence-based clinical practice guideline on adeno-associated virus (AAV) gene therapy for people with hemophilia (PwH). This guideline adds a new topic area to the broader WFH Guidelines for the Management of Hemophilia, providing the global bleeding disorders community with current, practical recommendations for this rapidly evolving treatment option.












